STRENGTHENING - Exact Sciences · Modeling Network (CISNET) Colorectal Cancer Working Group....
1
STRENGTHENING CLINICAL EVIDENCE FOR COLOGUARD IN 2015-16 INCREASING AMERICA’S SCREENING POPULATION 4 IN 10 COLOGUARD USERS NEVER PREVIOUSLY SCREENED COLOGUARD COMPARES FAVORABLY WITH ESTABLISHED SCREENING STRATEGIES MODELING SUPPORTS USING COLOGUARD EVERY THREE YEARS screened with colonoscopy never screened before Complications Life years gained per complication Deaths averted per complication screened only with FIT/FOBT Screening history of Cologuard users Source: Berger BM, Hooker A, Bethke L, Parton M, Myers T, Laffin J. Colorectal Cancer Screening With Multi-target Stool DNA-based Testing: Previous Screening History of the Initial Patient Cohort. (2015) ACG2015. Proceedings of the 80th Annual American College of Gastroenterology; 2015 Oct 16-21; Honolulu, HI. Am J Gastroenterol 110: S595-S628; doi:10.1038/ajg.2015.271 Source: Zauber A, Knudsen A, Rutter CM, Lansdorp-Vogelaar I, Kuntz KM; Writing Committee of the Cancer Intervention and Surveillance Modeling Network (CISNET) Colorectal Cancer Working Group. Evaluating the Benefits and Harms of Colorectal Cancer Screening Strategies: A Collaborative Modeling Approach. [accessed 2016 Jan 28]. 49% 42% 9% COLOGUARD INCREASES PATIENT COMPLIANCE STUDY HIGHLIGHTS OPPORTUNITY TO EXPAND SCREENING & DETECT CURABLE-STAGE CANCER Source: Prince M., Lester L., Chinawala R., Berger, B.M. Multi-target sDNA Increases Colorectal Cancer Screening Among Previously Non-com- pliant Patients: the USMD Physician Services Experience. AACR annual meeting, April 16 - 20, 2016, New Orleans, Louisiana, USA 15 14-15 9-10 9 18 17-20 23-28 23.9 1.6 1.5-1.7 2.0-2.4 2.1 COLOGUARD’S PERFORMANCE CONFIRMED IN RECENT STUDY Sources: 1) Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., ... Berger, B. M. (2014). Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med, 370(14), 1287-1297. doi:10.1056/NEJMoa1311194 2) Imperiale TF et al., N Engl J Med (2014) Redwood DG, Asay ED, Blake ID, et al . Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People. Mayo Clin Proc 2016; 91: 61-70. MODELING SUPPORTS COLOGARD AS COST-EFFECTIVE Source: Berger BM, Schroy PC, 3rd, Dinh TA. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness. Clin Colorectal Cancer 2015.Epub ahead of print. COLOGUARD ® cervical cancer breast cancer October 20152 March 20141 QALYs: Quality Adjusted Life Years Saved *clean colons have no need for biopsy $11,313 per QALYs 3 YEARS 3 YEARS 2 YEARS $15,500 per QALYs $30,000 per QALYs MAYO CLINIC STUDY COMPARES RESULTS OF UNBLINDED, BLINDED COLONOSCOPY KNOWLEDGE OF POSITIVE COLOGUARD IMPROVES COLONOSCOPY PERFORMANCE Source: Johnson D, Kisiel JB, Burger KN, et al. Su1044 Knowledge of a Positive Cologuard™ Result Improves Yield and Quality of Colonoscopy. Gastroenterology.150:S454. 100% 41% 93% 92% 42% 90% (10/10) (60/65) (31/76) (321/757) (296/318) (4002/4457) CANCER DETECTION PRECANCER DETECTION SPECIFICITY (CLEAN COLON*) Non-compliant Medicare patients Cologuard® compliance Cancers in curable stage * ; 21 advanced adenoma polyps discovered 2X more time spent on colonoscopy 46% + 393 88% 4 INVESTOR.EXACTSCIENCES.COM View Exact Sciences’ 2015 Annual Report: exactsciences.com/annual-report SUPERIOR BENEFITS-TO-HARMS PER 1,000 PATIENTS SCREENED Colonoscopy every 10 years Cologuard every 3 years *stage I and stage II
Transcript of STRENGTHENING - Exact Sciences · Modeling Network (CISNET) Colorectal Cancer Working Group....
STRENGTHENING CLINICAL EVIDENCE FOR COLOGUARD IN 2015-16
INCREASING AMERICA’S SCREENING POPULATION4 IN 10 COLOGUARD USERS NEVER PREVIOUSLY SCREENED
COLOGUARD COMPARES FAVORABLY WITH ESTABLISHED SCREENING STRATEGIES
MODELING SUPPORTS USING COLOGUARD EVERY THREE YEARS
screened with colonoscopy
never screened before
Complications
Life years gained per complication
Deaths averted per complication
screened only with FIT/FOBT
Screening history of Cologuard users
Source: Berger BM, Hooker A, Bethke L, Parton M, Myers T, La�n J. Colorectal Cancer Screening With Multi-target Stool DNA-based Testing: Previous Screening History of the Initial Patient Cohort. (2015) ACG2015. Proceedings of the 80th Annual American College of Gastroenterology; 2015 Oct 16-21; Honolulu, HI. Am J Gastroenterol 110: S595-S628; doi:10.1038/ajg.2015.271
Source: Zauber A, Knudsen A, Rutter CM, Lansdorp-Vogelaar I, Kuntz KM; Writing Committee of the Cancer Intervention and Surveillance Modeling Network (CISNET) Colorectal Cancer Working Group. Evaluating the Benefits and Harms of Colorectal Cancer Screening Strategies: A Collaborative Modeling Approach. [accessed 2016 Jan 28].
49%
42%9%
COLOGUARD INCREASES PATIENT COMPLIANCESTUDY HIGHLIGHTS OPPORTUNITY TO EXPAND SCREENING & DETECT CURABLE-STAGE CANCER
Source: Prince M., Lester L., Chinawala R., Berger, B.M. Multi-target sDNA Increases Colorectal Cancer Screening Among Previously Non-com-pliant Patients: the USMD Physician Services Experience. AACR annual meeting, April 16 - 20, 2016, New Orleans, Louisiana, USA
1514-15 9-10
9
1817-20 23-28
23.9
1.61.5-1.7 2.0-2.4
2.1
COLOGUARD’S PERFORMANCE CONFIRMED IN RECENT STUDY
Sources: 1) Imperiale, T. F., Ransoho�, D. F., Itzkowitz, S. H., Levin, T. R., Lavin, P., Lidgard, G. P., ... Berger, B. M. (2014). Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med, 370(14), 1287-1297. doi:10.1056/NEJMoa1311194
2) Imperiale TF et al., N Engl J Med (2014) Redwood DG, Asay ED, Blake ID, et al . Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People. Mayo Clin Proc 2016; 91: 61-70.
MODELING SUPPORTS COLOGARD AS COST-EFFECTIVE
Source: Berger BM, Schroy PC, 3rd, Dinh TA. Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the E�ect of the Intertest Interval on Clinical E�ectiveness. Clin Colorectal Cancer 2015.Epub ahead of print.
COLOGUARD®cervical cancer
breast cancer
October 20152March 20141
QALYs: Quality Adjusted Life Years Saved
*clean colons have no need for biopsy
$11,313per QALYs
3 YEARS 3 YEARS 2 YEARS
$15,500per QALYs
$30,000per QALYs
MAYO CLINIC STUDY COMPARES RESULTS OF UNBLINDED, BLINDED COLONOSCOPY
KNOWLEDGE OF POSITIVE COLOGUARD IMPROVES COLONOSCOPY PERFORMANCE
Source: Johnson D, Kisiel JB, Burger KN, et al. Su1044 Knowledge of a Positive Cologuard™ Result Improves Yield and Quality of Colonoscopy. Gastroenterology.150:S454.
100%
41%
93%
92%
42%
90%
(10/10)(60/65)
(31/76)(321/757)
(296/318)(4002/4457)
CANCER DETECTION
PRECANCER DETECTION
SPECIFICITY (CLEAN COLON*)
Non-compliant Medicare patients
Cologuard®compliance
Cancers in curable stage*; 21 advanced adenoma
polyps discovered
2Xmore time spent on colonoscopy
46%
+393 88% 4
INVESTOR.EXACTSCIENCES.COM
View Exact Sciences’ 2015 Annual Report: exactsciences.com/annual-report
SUPERIOR BENEFITS-TO-HARMS PER 1,000 PATIENTS SCREENED
Colonoscopy every 10 years
Cologuardevery 3 years
*stage I and stage II
